Join the Discussion

Will Oncologists Change Their Treatment Patterns Based on New Clinical Evidence?

Dawn Holcombe, MBA, FACMPE, ACHE

July 2018, Vol 8, No 7 - From the Editor

In medical parlance, there is a wide gap between the terms “prognostic” and “predictive.” At a plenary session at the 2018 American Society of Clinical Oncology (ASCO) meeting, results presented from the TAILORx clinical trial cast a spotlight on that gap, and narrowed it. The question now is, will physicians and patients take action and cease the use of chemotherapy when its effectiveness can be predictively deemed ineffective, despite the challenges of hope and habit? [ Read More ]

The Promise and Peril of Technology

Dawn Holcombe, MBA, FACMPE, ACHE

April 2018, Vol 8, No 4 - From the Editor

What seems like just a few years ago, oncology practice technology amounted to a billing system and an electronic medical records (EMR) system, possibly even a drug inventory management system. When a practice participated in quality or performance metrics, such as the American Society of Clinical Oncology Quality Oncology Practice Initiative, it was usually through the process of a manual chart review conducted for a subset of patients being treated by the group. [ Read More ]

Authority Over Medical Practices—Something to Watch

Dawn Holcombe, MBA, FACMPE, ACHE

February 2018, Vol 8, No 2 - From the Editor

In the snow-covered fields of New Hampshire, things have been heating up for medical practices that reconstitute and infuse drugs. In November 2017, the New Hampshire Board of Pharmacy paid surprise inspections to several medical practices (outside of oncology) to review their compliance with US Pharmacopeial Convention Chapter 797 (USP 797) standards for sterile compounding. [ Read More ]

Slowing Down to Move Forward: The Summer of 2017 May Be Pivotal for Oncology Practices

Dawn Holcombe, MBA, FACMPE, ACHE

July 2017, Vol 7, No 7 - From the Editor

This year has been more hectic for practice administrators than I have seen in decades. Practice administrators keep telling me they feel they are working harder and harder, and have so many more demands on the practice involving reporting, chasing reimbursement, securing access for their patients, and helping their physicians navigate the increasing demands on them, that it is just too hard to keep up. [ Read More ]

2017—the Year of the Huddle?

Dawn Holcombe, MBA, FACMPE, ACHE

February 2017, Vol 7, No 2 - From the Editor

In 2017, more than ever before, oncology practices of all sizes will ultimately be responsible for the quality and the continuity of the care that they provide to their patients. Notably, under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) and the Merit-based Incentive Payment System (MIPS), Medicare will be tracking performance and scores that practices accumulate through self-reporting or Medicare claims tracking. These performance metrics include quality measures, resource utilization, Advancing Care Information under MIPS, and the Clinical Practice Improvement Activities of MACRA. Practices that are participating in the Medicare Oncology Care Model (OCM) are subject to the MIPS measures, as well as the requirements and expectations for practice transformation under the OCM, although some OCM activities may also facilitate performance for the MIPS measures. [ Read More ]